Evgen Pharma Share Discussion Threads

[ardinno] 22/5/2020 14:59

I think the lack of updates is obviously a sign that they are just waiting for the right time to announce Elvis as the new CEO thus turning this into a sure-fire googolplex-bagger! Good luck all, love you lots :)

*insert old, already-digested RNS verbatim apropo of context*

Did I pass the audition?

[chuffer2] 22/5/2020 14:32

Doesn't sound like the sort of thing he would do?????
Lol, lol,lol

[toffeeman] 22/5/2020 14:00

I thought MM was doing a fab job of ramping.

[chuffer2] 22/5/2020 13:58

It's all gone quiet over here.
What we need is a really good pump with a series of endless posts.
Any takers??????
Lol

[moneymunch] 22/5/2020 11:43

Lol...Good for you.:-)

[toffeeman] 22/5/2020 11:37

just a mono not a multi :)

[moneymunch] 22/5/2020 11:29

ps Toffeeman, i assume through your judgement in share trading, you're a multi-millionaire, or aren't you that lucky??? ;-)

[moneymunch] 22/5/2020 11:24

Investors aren't perfectly rational, and some are more interested in covering their backsides than taking well judged risks. But the hypothesis is true-ish. And the truer it is, the harder it's going to be for anyone to beat the stock market.

Samuelson looked at the data and found - embarrassingly for the investment industry - that, indeed, in the long run, most professional investors didn't beat the market.

And while some did, good performance often didn't last. There's a lot of luck involved, and it's hard to distinguish that luck from skill.



........

Do we make our own luck? It is a question tackled with great insight by Oaktree Capital Chairman Howard Marks, one of The Value Perspective’s favourite investors, in his excellent memo to the firm’s clients, Getting lucky. We will pick out a few of his points on the way to making our own but, if you have not read it already, the whole memo really is worth a look.

Before addressing the role of luck in investment, Marks spends some time considering the part it plays in our lives in general. Using himself as an example, he notes all the ways “demographic luck” has contributed to his success – not least in winning what Warren Buffett has memorably described as “the ovarian lottery” as a result of being born in the US in the first place.

[moneymunch] 22/5/2020 11:19

Mr. Buffett’s investment style has been criticized by many over the decades. Trend followers and traders are especially critical of his record and philosophy, claiming that his results are the result of “luck, given the relatively few trades that made him so wealthy.”

[moneymunch] 22/5/2020 11:05

Lol....Good Luck to all holders except Toffeman. ;-)

[toffeeman] 22/5/2020 11:02

I hate the terminology GLA - I don't invest expecting good luck, I try to do it using good judgement.

[moneymunch] 22/5/2020 10:38

A nice 100k buy in anticipation of news..Gla ;-)

[toffeeman] 22/5/2020 09:47

No news is good news -------- OR bad news

[mesquida] 22/5/2020 09:36

Surely by now we should have seen one ( if not two ) RNS's to explain who was behind the exceptional volume that we saw the other day.

[moneymunch] 22/5/2020 07:32

News | 9 March 2020

Wellcome pledges up to $50 million to new initiative to speed development of COVID-19 treatments

Wellcome joins the Bill & Melinda Gates Foundation and Mastercard in launching a new initiative to speed the development of and access to therapies for COVID-19. Together they are committing up to $125 million in seed funding.

The COVID-19 Therapeutics Accelerator(opens in a new tab) will coordinate research efforts and remove barriers to drug development.

Currently there are no approved treatments for COVID-19. This new initiative aims to fill that gap by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The partners are committed to equal access, ensuring treatments are accessible and affordable in low-resource settings.

The Gates Foundation and Wellcome are each contributing up to $50 million, and the Mastercard Impact Fund is committing up to $25 million to the initiative. The Gates Foundation’s funding is part of its $100 million commitment to the COVID-19 response announced last month.

Dr Jeremy Farrar, Director of Wellcome, said: "Science is moving at a phenomenal pace against COVID-19, but to get ahead of this epidemic we need greater investment and to ensure research coordination. The Therapeutics Accelerator will allow us to do this for potential treatments with support for research, development, assessment and manufacturing."

He added: "Investing now, at scale, at risk and as a collective global effort is vital if we are to change the course of this epidemic. We welcome others to join us in this effort."

[moneymunch] 22/5/2020 06:39

Another potential avenue for funding, EVG have a MoU with Dundee University, and so if SFX-01 is one of the drugs identified in the screening process, then perhaps further funds from Bill and co would be forthcoming for any potential Covid-19 patient trials??? Gla :-)

....

Coronavirus: Dundee Uni researchers land six-figure funding to help rapid research into Covid-19 antidote

2 weeks ago

Dundee University has shared a six-figure funding boost to accelerate the quest for a potential Covid-19 antidote.

In a project funded by benefactors including Microsoft founder Bill Gates, Dundee and Glasgow Universities have been given £225,000 to screen existing medical treatments in a bid to determine their potential effectiveness against SARS-CoV-2, the virus which causes Covid-19.

The move has been funded by Covid-19 Therapeutics Accelerator, an initiative launched by the Bill and Melinda Gates Foundation, Wellcome, and Mastercard to speed up the response to the coronavirus.

The University of Dundee Drug Discovery Unit (DDU) and researchers at the MRC-University of Glasgow Centre for Virus Research (CVR) will work together to rapidly screen a large collection of existing approved medical treatments for other diseases.

They will also conduct research into whether any combination of the molecules may have anti-SARS-CoV-2 potential when acting together against the virus.

As SARS-CoV-2 is an emerging virus, there are currently no known effective medicines for patients who require hospitalisation and treatment.

However, the team of Scottish-based scientists believe it may be possible to rapidly repurpose existing therapeutics to combat the COVID-19 pandemic.

Professor Paul Wyatt, head of the DDU, said: “This is an exciting opportunity to partner the virology expertise in the CVR, with the drug discovery expertise in the DDU, to seek to find new treatments for this destructive disease.

“Even if it does not identify medicines that can be used immediately it could give us good start points for the development of new drugs for the future.”

Professor Massimo Palmarini, Director of the CVR, said, “There is an urgent need to find treatments that will be effective against the SARS-CoV-2 virus, as millions of people around the world continue to be exposed to and fall ill with this new coronavirus.

“However, the usual mechanisms for developing treatments can be lengthy, and so projects like this, searching through treatments that already exist, could save time and help to save lives.”

.......


5/12/19

Memorandum of Understanding with The University of Dundee

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."

[moneymunch] 22/5/2020 06:15

Why, does he hate Man U 2..? ;-)

[toffeeman] 21/5/2020 22:06

MM you are sounding more and more like Stig each day.

[bumpa33] 21/5/2020 22:02

the 200k was a buy, at the mid, not the bid, no late report afaics

[moneymunch] 21/5/2020 21:20

I hate Man United, but....:-)

[moneymunch] 21/5/2020 21:13

Perfectly poised and primed....Watch this Space!!! :-)

[moneymunch] 21/5/2020 21:12

Lol , and so I guess you're both hoping the news won't be good...ha ha ha....the 200k looked like a buy to me along with the 50k late reported trade...the only sells were small fry, you know the type...ho ho ho...Potential Transformational news is getting closer...Gla Holders...Significant UPSIDE on funding confirmation for SFX-01 patient trials for Covid-19...:-)

[euclid5] 21/5/2020 20:29

the 200,000 trade was at the bid price 13.25p - so it was a sell - which has bought the bid price down to 13p